Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer

被引：0
|
作者：
Dong Ha Kim
Yun Jung Choi
Seon Ye Kim
Jung-Eun Lee
Ki Jung Sung
Young Hoon Sung
Woo Sung Kim
Sung-Eun Kim
Hyung Chul Ryu
Jae Sun Kim
Lu Guangying
Chang-Min Choi
Jin Kyung Rho
Jae Cheol Lee
机构：
[1] University of Ulsan,Department of Pulmonology and Critical Care Medicine, Asan Medical Center
[2] College of Medicine,Asan Institute for Life Sciences, Asan Medical Center
[3] University of Ulsan,Department of Convergence Medicine, Asan Medical Center
[4] College of Medicine,East China University of Science and Technology
[5] University of Ulsan,Department of Oncology, Asan Medical Center
[6] College of Medicine,Department of Asan Institute for Life Sciences, College of Medicine
[7] Oncobix,Department of Oncology, Asan Medical Center
[8] J2H Biotech,undefined
[9] College of Pharmacy,undefined
[10] University of Ulsan,undefined
[11] College of Medicine,undefined
[12] University of Ulsan,undefined
[13] University of Ulsan College of Medicine,undefined
来源：
Targeted Oncology | 2018年 / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：389 / 398
页数：9
相关论文
共 50 条
  • [21] XHL11, a novel selective EGFR inhibitor, overcomes EGFRT790M-mediated resistance in non-small cell lung cancer
    Li, Yi
    Yu, Qing-Long
    Li, Tong-Fang
    Xiao, Ya-Ni
    Zhang, Li
    Zhang, Qiu-Yan
    Ren, Chun-Guang
    Xie, Hong-Lei
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 907
  • [22] Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
    Shimamura, Takeshi
    Li, Danan
    Ji, Hongbin
    Haringsma, Henry J.
    Liniker, Elizabeth
    Borgman, Christa L.
    Lowell, April M.
    Minami, Yuko
    McNamara, Kate
    Perera, Samanthi A.
    Zaghlul, Sara
    Thomas, Roman K.
    Greulich, Heidi
    Kobayashi, Susumu
    Chirieac, Lucian R.
    Padera, Robert F.
    Kubo, Shigeto
    Takahashi, Masaya
    Tenen, Daniel G.
    Meyerson, Matthew
    Wong, Kwok-Kin
    Shapiro, Geoffrey I.
    [J]. CANCER RESEARCH, 2008, 68 (14) : 5827 - 5838
  • [23] The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer
    An, Baijiao
    Pan, Tingting
    Hu, Jinhui
    Pang, Yanqing
    Huang, Ling
    Chan, Albert S. C.
    Li, Xingshu
    Yan, Jun
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 183
  • [24] YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFRL858R, T790M-mutant resistance in vitro and in vivo
    Zhang, Zhang
    Zou, Jian
    Yu, Lei
    Luo, Jinfeng
    Li, Yan
    Tu, Zhengchao
    Ren, Xiaomei
    Wei, Hongcheng
    Song, Liyan
    Lu, Xiaoyun
    Ding, Ke
    [J]. CANCER MEDICINE, 2018, 7 (04): : 1430 - 1439
  • [25] Discovery of a novel and potent mutant-selective inhibitor of PI3Kα
    Gao, Mingming
    Qi, Chao
    Li, Zhentian
    Fan, Qipeng
    Wang, Liyang
    Zhou, Fei
    You, Lin
    Zheng, Hewen
    Li, Yu
    Wu, Liangxing
    Yao, Wenqing
    Liu, Phillip C.
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [26] Discovery of rociletinib (CO-1686), a mutant-selective covalent inhibitor of EGFR
    Niu, Deqiang
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [27] TAS-121, a highly potent and mutant-specific EGFR inhibitor, overcomes T790M-acquired resistance with promising antitumor activity through specific inhibition of mutant EGFR signaling
    Kato, M.
    Miyadera, K.
    Ito, K.
    Aoyagi, Y.
    Hashimoto, A.
    Yonekura, K.
    Iwasawa, Y.
    Utsugi, T.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 128 - 128
  • [28] First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer
    Zheng, Jing
    Shen, Lisha
    Jiang, Nan
    Zhu, Yanping
    Wu, Lihua
    Cao, He
    Sun, Wenjia
    Zhou, Jianya
    Zhou, Jianying
    [J]. CLINICAL LUNG CANCER, 2020, 21 (06) : 509 - +
  • [29] Discovery of a potent covalent mutant-selective EGFR inhibitor - the journey from high throughput screening to EGF816
    Lelais, Gerald
    Epple, Robert
    Michellys, Pierre-Yves
    Marsilje, Thomas H.
    Long, Yun
    McNeill, Matthew
    Chen, Bei
    Lu, Wenshuo
    Bursulaya, Badry
    DiDonato, Michael
    Jia, Yong
    Kasibhatla, Shailaja
    Li, Chun
    Matushansky, Igor
    Bender, Steven
    [J]. CANCER RESEARCH, 2015, 75
  • [30] Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer
    Wang, Chengde
    Wang, Wei
    Wang, Chaoyang
    Tang, Yijun
    Tian, Hui
    [J]. ONCOLOGY LETTERS, 2015, 10 (04) : 2063 - 2066
12345